Navigation Links
A New Drug for Halting Metastatic Kidney Cancer

A recent research reports the efficacy of a pharmaceutical drug named Sunitinib in halting the progress of metastatic kidney cancer. A comparative study of interferon and// sunitinib treatments found that sunitinib is more efficient in halting the progress of metastatic kidney cancer.

The work was published recently in the prestigious international medical journal, The New England Journal of Medicine and involved medical co-researchers from the Oncology Department of the University Hospital of Navarra, in collaboration with the Clinical Trials Area of the same Department.

To date the usual treatment for kidney cancer of a metastatic nature has been based solely on immunotherapy. In phase III of the research sunitinib was compared with interferon (a type of immunotherapy) in 750 patients with metastatic kidney cancer and it was shown that sunitinib is more efficient in halting the progress of the disease. 101 medical centres from all over the world took part in the research.

Given the short period of follow-up in the research, the effect of the treatment on survival rates could not be corroborated. Although, in general, the treatment is well tolerated, certain side effects can occur and have to be taken into consideration - hypothyroidism, high blood pressure and fatigue.

Metastatic kidney cancer is one of the cancer pathologies the treatment of which has made least progress in recent years. The usual treatment with immunotherapy had not shown clearly positive results in many patients. Sunitinib is one of the few pharmaceutical drugs that provide clear improvements in this type of cancer.

The mechanism of functioning of sunitinib is in blocking the generation of new blood vessels. Tumors, in order to grow, need to develop blood vessels and this pharmaceutical drug impedes their growth, blocking a factor known as VEGF, and other similar ones, which stimulate vascular growth. The use of sunitinib in Spain is t o be approved shortly for the treatment of kidney cancer with metastasis although, at the University Hospital, it has been employed with over 40 patients for the last two years, using clinical trials.

Source-Eurekalert
PRI
'"/>




Related medicine news :

1. Anti-Retrovirals Capable of Halting Mental Illness in HIV Patients
2. Cholesterol-lowering Drug Effective at Halting Early Atherosclerosis
3. IMP3 the Novel Biomarker for Metastatic Cancer
4. Researchers Find Stem-cell Therapy Effective in Targeting Metastatic Cancer
5. Is Diabetes the Leading Cause of Kidney Failure in India
6. Kidney Stones - Interesting New Research implicates bacteria as its cause
7. Moderate Use of Analgesics - Not Associated With Kidney Dysfunction
8. New Dietary Approach To Manage Kidney Stones
9. Kidney cancer on the rise
10. Kidney function can be affected by lead exposure
11. Kidney Failure after Non-Kidney Transplants
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... , ... February 23, 2017 , ... Hamlin Dental Group ... that they are sponsoring a raffle. Throughout the month of February, patients who visit ... a gift card for a dinner for two at the Cheesecake Factory. , ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... will host a diverse symposium on “Doping in Sport: How the ... Sheppard Mullin Richter & Hampton LLP. The symposium will be held at Pepperdine ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... and uncertainty in clinical trials, today announced that Premier Research, a leading clinical ... solution. , Clinical trials are becoming increasingly complex, due in part to an ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist Dr. Mahnaz ... a new Indiegogo campaign . Individuals are now able to contribute to the ... area, either as a participating patient or through an Indiegogo donation. The entirety of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... YORK , Feb. 23, 2017  Genesis Healthcare ... Company. The announcement was made by Bill Monast ... David Hartley and Nathan Feltman , executives ... Genesis Healthcare Services, LLC. This acquisition ... largest provider of technology enabled durable medical equipment (DME) ...
(Date:2/23/2017)... Feb. 23, 2017 Nevro Corp. (NYSE: NVRO), a ... for the treatment of chronic pain, today reported financial results ... 2016. 2016 Accomplishment & Highlights: ... 2016, an increase of 228% as reported, over the prior ... an increase of 612% over the prior year ...
(Date:2/23/2017)... , Feb. 23, 2017 Research and Markets ... and Strategies - 2016" report to their offering. ... The latest research Fibromyalgia ... and benchmarks in the global Fibromyalgia market. The research ... key drugs marketed for Fibromyalgia and their clinical attributes? How are ...
Breaking Medicine Technology: